Please login to the form below

Not currently logged in
Email:
Password:

Lilly/Boehringer diabetes drug approved

The US Food and Drug Administration has granted marketing approval to a type 2 diabetes drug developed through a partnership between Lilly and Boehringer Ingelheim

The US Food and Drug Administration (FDA) has granted marketing approval to a type 2 diabetes drug developed through a partnership between Lilly and Boehringer Ingelheim.

Approval of the drug, Tradjenta (linagliptin), is the first regulatory milestone in the companies' worldwide diabetes alliance since the partnership was formed in January of this year. 

Tradjenta is indicated to lower blood sugar in adults when used in conjunction with a diet and exercise programme. The drug can be used as monotherapy or in combination with other commonly prescribed diabetes medications. 

The therapy increases the level of hormones that stimulate the release of insulin after a meal by blocking the enzyme dipeptidyl peptidase-4 (DPP-4). It is the first of the DPP-4 inhibitors to be approved at one dosage strength (5 mg, once daily), with no dose adjustment necessary in patients with kidney or liver impairment.

The approval was based on a New Drug Application (NDA) that contained data from eight double-blind, placebo-controlled clinical studies involving about 3,800 patients with type 2 diabetes.

Tradjenta is currently under regulatory review in the EU and Japan. The product will be available as a tablet that can be taken with or without food.

"This approval provides another treatment option for the millions of Americans with Type 2 diabetes," said Mary Parks, director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research. "It is effective when used alone or when added to existing treatment regimens."

4th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications is a fresh thinking health and medical communications agency. Our team is made up of experienced and...

Latest intelligence

Is telehealth delivering on its promises?
Using new digital technologies to help patients see their doctors online and not need to attend their surgery can help save time and money - but just how well is...
Channel purpose, change lives
GCI Health's Laura Starr on the power of creativity in health and wellness, all founded upon authentic brand purpose....
Wearables: the tangible product of the patient revolution
As the relationship between the patient and his doctor evolve, we look at how new technology is playing its part...

Infographics